2021
Improving hematology/oncology clinical research recruitment via universal prescreening: The VA Connecticut (VACT) Cancer Center experience.
Xiang J, Roy A, Summers C, Delvy M, O'Donovan J, Christensen J, Perry L, Connery D, Rose M, Chao H. Improving hematology/oncology clinical research recruitment via universal prescreening: The VA Connecticut (VACT) Cancer Center experience. Journal Of Clinical Oncology 2021, 39: 79-79. DOI: 10.1200/jco.2020.39.28_suppl.79.Peer-Reviewed Original ResearchLung cancer patientsCancer CenterClinical research recruitmentStudy enrollmentCancer patientsClinical trialsPotential eligibilityEligibility criteriaNew lung cancer patientsResearch enrollmentPotential study patientsCancer Center experienceTherapeutic clinical trialsNumber of patientsDiagnosis of cancerResearch recruitmentEligible patientsMalignancy workupPrimary oncologistStudy patientsChart reviewClinic visitsGenitourinary cancersPatient demographicsCenter experience
2010
Prostate Cancer, Comorbidity, and Participation in Randomized Controlled Trials of Therapy
Chao H, Mayer T, Concato J, Rose M, Uchio E, Kelly K. Prostate Cancer, Comorbidity, and Participation in Randomized Controlled Trials of Therapy. Journal Of Investigative Medicine 2010, 58: 566. DOI: 10.2310/jim.0b013e3181cf9002.Peer-Reviewed Original ResearchCastrate-resistant prostate cancerPhase 3 RCTsProstate cancerClinical settingPhase 3 clinical trialsVeterans Affairs Connecticut Healthcare SystemGeneral oncology practiceAbnormal laboratory valuesPopulation of patientsRandomized Controlled TrialsComplete medical recordsSerious medical conditionProportion of menBackground RandomizedChemotherapy regimensCRPC patientsControlled TrialsMedical recordsClinical trialsOncology practiceInclusion criteriaLaboratory valuesCardiac diseaseMedical conditionsClinical care